Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own”

Jim Cramer on Boston Scientific: “This Whole Cohort Is Just Too Hard to Own” Syeda Seirut Javed Tue, June 23, 2026 at 4:41 PM GMT+2 1 min read BSX ABT MDT Boston Scientific Corporation (NYSE: BSX ) was among the stocks Jim Cramer discussed as he said that the Iran peace negotiations could trigger an oil glut, cool inflation, and pull interest rates down . A caller asked about Cramer's thoughts on the stock, and he replied: Now, I gotta tell you something, I was shocked at the decline in this. They have this one really good product.

The sales didn't come through, and the stock has been on a major… decline, but so has Abbott, so has Medtronic. The device sector is from Hades. If you're willing to wait, I still don't know when their next edition's going to come out to make you feel better… This whole cohort is just too hard to own.

And when I see that, what I think is somebody knows something I don't. I hate that. I say no to Boston Scientific.

Photo by Adam Nowakowski on Unsplash Boston Scientific Corporation (NYSE:BSX) manufactures medical devices for different fields, including cardiology, neurology, and urology. Some of the company's products include heart-monitoring implants, spinal cord stimulators, and diagnostic tools for gastrointestinal conditions and cancer treatment. While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk.

If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock . READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years   Disclosure: None. Follow Insider Monkey on Google News .